Literature DB >> 20956948

PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation.

R Deng1, J Tang, J-G Ma, S-P Chen, L-P Xia, W-J Zhou, D-D Li, G-K Feng, Y-X Zeng, X-F Zhu.   

Abstract

An elevated DNA-repair capacity in cancer cells leads to radiation resistance and severely limits the efficacy of radiation therapy. Activation of Akt is tightly associated with resistance to radiotherapy, and Mre11 protein has important role during the repair of DNA double-strand breaks (DSBs). In this report, our results showed that inhibition of Akt activity impaired the repair of DSBs in CNE2 cells, whereas activated Akt promoted the repair of DSBs in HeLa cells. Knockdown of Mre11 also impaired the process of DSB repair in both these two cell lines. More importantly, we found that Akt could regulate Mre11 expression. Inhibition of Akt activity by small interfering RNA or LY294002 efficiently downregulated the Mre11 expression in CNE2 cells, and transfection with myr-Akt plasmid in HeLa cells upregulated the Mre11 expression. In addition, luciferase reporter analysis revealed that Mre11 reporter activity increased after transfection with myr-Akt1 plasmids, and this myr-Akt1-induced transcriptional activity was blocked in the presence of LY294002. Further study showed GSK3β/β-catenin/LEF-1 pathway was involved in this regulation. Knockdown of β-catenin or LEF-1 led to the downregulation of Mre11, whereas overexpression of β-catenin led to upregulation of Mre11. The chromatin immunoprecipitation assay assay showed β-catenin/LEF-1 heterodimer could directly bind to the promoter of Mre11 in vivo. And the luciferase activity of the pGL3-Mre11 and pGL3-Lef increased in HeLa cells following β-catenin plasmid co-transfected, but was abolished when the LEF-1-binding conserved sequences of Mre11 promoter were mutated. These results together support Akt can upregulate the expression of Mre11 through GSK3β/ β-catenin/LEF pathway to elevate DSB-repair capacity in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956948     DOI: 10.1038/onc.2010.467

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer.

Authors:  Sylvain Ferrandon; Jennifer DeVecchio; Leonardo Duraes; Hanumant Chouhan; Georgios Karagkounis; Jacqueline Davenport; Matthew Orloff; David Liska; Matthew F Kalady
Journal:  Cancer Res       Date:  2019-11-08       Impact factor: 12.701

2.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

3.  Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer.

Authors:  Karim Nacerddine; Jean-Bernard Beaudry; Vasudeva Ginjala; Bart Westerman; Francesca Mattiroli; Ji-Ying Song; Henk van der Poel; Olga Balagué Ponz; Colin Pritchard; Paulien Cornelissen-Steijger; John Zevenhoven; Ellen Tanger; Titia K Sixma; Shridar Ganesan; Maarten van Lohuizen
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

Review 4.  Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Authors:  Pau Castel; Eneda Toska; Zachary S Zumsteg; F Javier Carmona; Moshe Elkabets; Ana Bosch; Maurizio Scaltriti
Journal:  Mol Cell Oncol       Date:  2014-10-29

5.  ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells.

Authors:  Jing-Hong Chen; Peng Zhang; Wen-Dan Chen; Dan-Dan Li; Xiao-Qi Wu; Rong Deng; Lin Jiao; Xuan Li; Jiao Ji; Gong-Kan Feng; Yi-Xin Zeng; Jian-Wei Jiang; Xiao-Feng Zhu
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

6.  Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Authors:  Terence M Williams; Athena R Flecha; Paul Keller; Ashwin Ram; David Karnak; Stefanie Galbán; Craig J Galbán; Brian D Ross; Theodore S Lawrence; Alnawaz Rehemtulla; Judith Sebolt-Leopold
Journal:  Mol Cancer Ther       Date:  2012-03-12       Impact factor: 6.261

7.  The microRNA-423-3p-Bim Axis Promotes Cancer Progression and Activates Oncogenic Autophagy in Gastric Cancer.

Authors:  Pengfei Kong; Xiaofeng Zhu; Qirong Geng; Liangping Xia; Xiaowei Sun; Yingbo Chen; Wei Li; Zhiwei Zhou; Youqing Zhan; Dazhi Xu
Journal:  Mol Ther       Date:  2017-02-21       Impact factor: 11.454

8.  Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.

Authors:  Zachary S Zumsteg; Natasha Morse; Gabriel Krigsfeld; Gaorav Gupta; Daniel S Higginson; Nancy Y Lee; Luc Morris; Ian Ganly; Stephan L Shiao; Simon N Powell; Christine H Chung; Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2015-11-20       Impact factor: 12.531

9.  Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.

Authors:  Euphemia Leung; Gordon W Rewcastle; Wayne R Joseph; Rhonda J Rosengren; Lesley Larsen; Bruce C Baguley
Journal:  Invest New Drugs       Date:  2011-11-22       Impact factor: 3.850

10.  Co-inhibition of epidermal growth factor receptor and insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells.

Authors:  Ping Li; Marlon R Veldwijk; Qing Zhang; Zhao-Bin Li; Wen-Cai Xu; Shen Fu
Journal:  BMC Cancer       Date:  2013-06-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.